LLY
Lilly’s still in beast mode
Eli Lilly just posted second-quarter 2026 results that read a lot like: yes, the obesity boom is still booming. Revenue surged 48% to $23.0 billion, with Mounjaro and Zepbound doing the heavy lifting as volume kept climbing.
The bottom line got fatter too
EPS came in at $7.94 on a reported basis, up 26%, and $8.38 on a non-GAAP basis, up 33%. That’s the kind of growth that makes investors sit up a little straighter, because it says Lilly isn’t just selling more—it’s turning that demand into real earnings power.
Why investors care
The other shoe drop here is guidance: Lilly raised its full-year outlook. Translation: management is seeing enough strength in the business to lean more optimistic, which is exactly what shareholders want to hear when the market is already pricing in big expectations.
A few things stand out:
- Mounjaro and Zepbound are still the stars of the show
- Revenue growth is broad enough to keep the story sticky, not just flashy
- Higher guidance suggests the pipeline and current demand are both doing some of the heavy lifting
Big picture: Lilly’s not acting like a one-hit wonder. It’s starting to look more like a full-on franchise, and that tends to keep Wall Street interested.